BCL2 and acute myeloid leukemia: In patients receiving intensive chemotherapy for AML, the overexpression of anti-apoptotic BCL-2 family members has been associated with poor outcome (earlier relapse, reduced CR rates and overall survival-OS), (Del Poeta et al., 2003; Mehta et al., 2013).